The global antidiabetic drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The disease burden of diabetes is high and growing in every country, fueled by an increase in the prevalence of obesity and unhealthy lifestyles throughout the globe. The market growth is attributed owing to the rising incidence of diabetes and the growing number of health awareness initiatives launched by various health organizations. Presently, type-1 diabetes accounts for roughly 10% of all the global diabetes cases (with type-2 accounting for the remaining share). The factor contributing to the growth of the global antidiabetic drugs market include the rising healthcare expenditure on the disease. According to the International Diabetes Federation (IDF), the annual global health spending on diabetes was about $760 billion in 2019.
To Request a Sample of our Report on Antidiabetic Drugs Market: https://www.omrglobal.com/request-sample/antidiabetic-drugs-market
Some key players operating in the market include Eli Lilly and Co., AstraZeneca plc, and Sanofi S.A., among others. The market players are eyeing to strengthen their position in the market by adopting various strategies such as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) was authorized by the US FDA in January 2020 to reduce blood sugar in individuals with type-2 diabetes. Trijardy XR is a combination of three type-2 diabetes medications in a single tablet. Novo Nordisk announced in September 2019 that the US FDA had authorized Rybelsus (semaglutide) oral tablets for adult patients with type 2 diabetes. Rybelsus is the first non-injected glucagon-like peptide (GLP-1) receptor protein therapy to get FDA clearance in the US.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
- By Diabetes Type
- By Patient Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Eli Lilly and Co., AstraZeneca plc, and Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A full Report of Antidiabetic Drugs Market is Available @ https://www.omrglobal.com/industry-reports/antidiabetic-drugs-market
Global Antidiabetic Drugs Market Report by Segment
By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
By Patient Type
- Adult
- Pediatric
- Geriatric
Global Antidiabetic Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
